Revolutionizing Cancer Treatment: C4 Therapeutics Unveils Groundbreaking Results from CFT1946 Monotherapy Trial at ESMO Congress 2024
Exciting News for C4 Therapeutics, Inc.: Abstract Released Highlighting Favorable Safety Profile and Early Anti-Tumor Activity Investor Webcast Scheduled for September 13, 2024 WATERTOWN, Mass., Sept. 08, 2024 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC) announced today that the abstract sharing clinical data from its Phase 1 clinical trial of CFT1946 was released…